The prognosis of haploidentical hematopoietic stem cell transplantation in infants and patients under 3 years old with acute leukemia

Guan‐hua Hu,Xiao‐hui Zhang,Yu Wang,Lan‐ping Xu,Xin‐lin Hou,Yi‐fei Cheng,Xiao‐jun Huang

DOI: https://doi.org/10.1111/ctr.15247

2024-02-21

Clinical Transplantation

Abstract:Background The role of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in patients <3 years of age remains controversial. Data on haploidentical donor (HID) transplants in this age group is limited. Patients and Methods We retrospectively analyzed the prognosis of 97 patients with acute leukemia aged <3 years who underwent HID transplantation at our institute. Results With a median follow‐up of 45 months, the 3‐year disease‐free survival (DFS), overall survival (OS), and 3‐year cumulative incidence rate of treatment‐related mortality were 69.3% (95% confidence interval (CI): 59.9%–78.7%), 74.2% (95% CI: 65.2%–83.2%), and 3.6% (95% CI: 0.9%–9.7%) in all 97 patients, respectively. The 3‐year DFS and OS rate in patients diagnosed <1 year and patients diagnosed ≥1 year were comparable: 77.8% (95% CI: 62.2%–93.4%) versus 66.3% (95% CI: 55.0%–77.6%, p = .253) and 82.5% (95% CI: 66.3–98.7%) versus 72.8% (95% CI: 61.9%–83.7%, p = .153), respectively. At the last follow‐up, 23 patients had died, and 20 had died of relapse. Multivariate analysis revealed that positive pre‐HSCT flow cytometric minimal residual disease (hazard ratio 5.605, p = .000) and AML‐M7 expression (hazard ratio 2.906, p = .014) were independent adverse prognostic variables for relapse. Conclusions HID transplantation is potent and safe for infants and young patients with acute leukemia. Relapse is the primary cause of treatment failure.

surgery,transplantation